Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01930981 · ClinicalTrials.gov registry record
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
A clinical trial of Hematologic Malignancies and Other Diagnoses, Comorbidities, and Complications, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- 252
- Enrollment target
- 1
- Study location
NCT01930981 is a study of Hematologic Malignancies and Other Diagnoses, Comorbidities, and Complications that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 252 participants, below the 2,706-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01930981, a study of Hematologic Malignancies and Other Diagnoses, Comorbidities, and Complications, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- 252 participants
- Enrollment target
- 1
- Study location
Study Summary
We are interested in studying whether and how medical problems other than primary cancer before hematopoietic cell transplantation would impact the profiles of quality of life and toxicities post-transplantation for patients with blood cancers. We want to see if by assessing comorbidities (such as diabetes) early on, we can identify those patients who will have more toxicities or limitations in their quality of life after transplant. The generated information could set the stage for future intervention studies aiming to improve quality of life for patients with blood cancers after transplantation.
Conditions Studied
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01930981
The ClinicalTrials.gov registry entry for NCT01930981 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,706-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (91% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 0 interventions.
NCT01930981 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01930981 about?
NCT01930981 is a clinical study titled "Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life". We are interested in studying whether and how medical problems other than primary cancer before hematopoietic cell transplantation would impact the profiles of quality of life and toxicities post-transplantation for patients with blood cancers. We want to see if by assessing comorbidities (such as d...
What is the current status of trial NCT01930981?
This trial is currently completed. The enrollment target is 252 participants. The study started on 2012-10. Estimated completion is 2016-06.
What conditions does trial NCT01930981 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Other Diagnoses, Comorbidities, and Complications.
Who is sponsoring clinical trial NCT01930981?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01930981 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
RECRUITING · NA
Explore more on PlainTrial
Hematologic Malignancies
All registered trials for this condition
Other Diagnoses, Comorbidities, and Complications
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.